A Phase 1 interventional study of Baxdrostat and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants.
This is a randomised, placebo-controlled, double-blind, 4-way crossover TQT study to assess the effect of single oral doses of baxdrostat on the QTcF compared to placebo using a concentration-QTcF analysis, and with open-label moxifloxacin as positive control, in 28 healthy participants, performed at a single clinical unit.
The study will comprise of:
Participants will each receive a single dose of all treatments in a cross-over design over 4 treatment periods. Participants will be randomised to 1 of 4 treatment sequences with equal allocation regarded as a Williams design of order 4.
Treatment Periods will be separated by a washout period of at least 7 days but no more than 9 days.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (ABCD) in a crossover design with a washout period of at least 7 days between each study dose administration.
Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin
Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (BDAC) in a crossover design with a washout period of at least 7 days between each study dose administration.
Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin
Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (CADB) in a crossover design with a washout period of at least 7 days between each study dose administration.
Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin
Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (DCBA) in a crossover design with a washout period of at least 7 days between each study dose administration.
Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin
Participants will receive baxdrostat as two separate doses.
Participants will receive baxdrostat matching placebo.
Participants will receive a single dose moxifloxacin
Placebo corrected change from baseline in QTcF (ΔΔQTcF)
The effect of single doses of baxdrostat on QTcF compared to placebo using a concentration-QTcF analysis will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Heart Rate (HR)
The effect of baxdrostat on HR will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
RR interval
The effect of baxdrostat on RR interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
PR interval
The effect of baxdrostat on PR interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
QRS interval
The effect of baxdrostat on QRS interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Change from baseline in Heart rate (ΔHR)
The effect of baxdrostat on HR will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
QT interval
The effect of baxdrostat on QT interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Change from baseline in RR interval (ΔRR)
The effect of baxdrostat on ΔRR interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Change from baseline in PR interval (ΔPR)
The effect of baxdrostat on ΔPR interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Change from baseline in QRS interval (ΔQRS)
The effect of baxdrostat on ΔQRS interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Change from baseline in QTcF (ΔQTcF)
The effect of baxdrostat on ΔQTcF will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Change from baseline in QT interval (ΔQT)
The effect of baxdrostat on ΔQT interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Number of participants with significant change in QTcF
The presence of categorical outliers for QTcF after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Number of participants with significant change in PR interval
The presence of categorical outliers for PR interval after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Number of participants with significant change in QRS interval
The presence of categorical outliers for QRS interval after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Number of participants with significant change in RR interval
The presence of categorical outliers for RR interval after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Number of participants with significant change in QT interval
The presence of categorical outliers for QT interval after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Number of participants with significant change in HR
The presence of categorical outliers for HR after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Placebo corrected change from baseline in HR (ΔΔHR)
The effect of baxdrostat on ΔΔHR will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Placebo corrected change from baseline in RR interval (ΔΔRR)
The effect of baxdrostat on ΔΔRR interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Placebo corrected change from baseline in PR interval (ΔΔPR)
The effect of baxdrostat on ΔΔPR interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
Placebo corrected change from baseline in QRS (ΔΔQRS)
The effect of baxdrostat on ΔΔQRS interval will be assessed.
Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose
AUClast of Baxdrostat
The PK of baxdrostat will be assessed.
Time frame: Day 1 to Day 3
AUCinf of Baxdrostat
The PK of baxdrostat will be assessed.
Time frame: Day 1 to Day 3
Maximum observed plasma peak concentration (Cmax) of baxdrostat
The PK of baxdrostat will be assessed.
Time frame: Day 1 to Day 3
Time to reach peak or maximum observed concentration (Tmax) of baxdrostat
The PK of baxdrostat will be assessed.
Time frame: Day 1 to Day 3
Number of participants with Adverse Events (AEs)
The safety and tolerability of baxdrostat will be assessed.
Time frame: Day 1 to last day of follow-up (approximately 7 to 10 days after the last dose)
Number of participants with Adverse events of special interest
The safety and tolerability of baxdrostat will be assessed. For this clinical study, AESIs include the following: hyperkalaemia, hyponatraemia, and hypotension events that require intervention.
Time frame: Day 1 to last day of follow-up (approximately 7 to 10 days after the last dose)
Number of treatment-emergent changes in T-wave morphology
Morphological changes in the T-wave after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Number of treatment-emergent changes in U-waves presence and morphology
Morphological changes in the U wave after baxdrostat administration will be assessed.
Time frame: Day 1 to Day 3
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Feb 2024 to primary completion in May 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Baxdrostat · Moxifloxacin